NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

"The Company cannot make partial disclosures during this process and cannot comment on the Phase III trial schedule"

Of course the "process" could end any day they deem necessary to suit their agenda. I am not myself expecting any significant news at the ASM, but the LL participation later this evening is something of an oddity. On one hand when you look at the details, it is clearly targeted at a student audience with pre-test and post-test with the following course objectives:-

LEARNING OBJECTIVES:

1. Apply knowledge regarding the challenges of using immune therapy in treating glioblastoma
2. Design clinical trials involving surgical endpoints for glioblastoma.
3. Compare historical clinical trials with new and innovative clinical trial designs.

But on the other hand, the course title of:-

"This webinar titled Brain Tumor Clinical Trial Update"

certainly makes one think...